Close Menu
Home › Freenome Raises $65M in Series A Funds

Freenome Raises $65M in Series A Funds

Mar 01, 2017

NEW YORK (GenomeWeb) – Palo Alto, California-based Freenome announced today that it has raised $65 million in Series A funding, which it will put toward conducting clinical trials to validate its non-invasive, early cancer detection technology.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25
Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

What's Popular?

In Molecular Diagnostics

  1. Eurofins Acquires Transplant Genomics

  2. Illumina, AnchorDx to Develop Genomic Cancer Tests for Chinese Market

  3. Liquid Biopsy Assay From MSKCC Approved by New York State

  4. FDNA, PerkinElmer Form Genetic Testing Technology Alliance

  5. Liquid Biopsy Monitoring, Surveillance Efforts Accelerate Across Cancer Types and Technologies

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.